ClinicalTrials.gg
Not yet recruitingNCT07354659Updated Jan 21, 2026

Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above

A Phase 2 interventional study of A zoster mRNA vaccine SYS6017 and Placebo in Herpes Zoster, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Not yet recruiting. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. We are conducting a study entitled "A Randomized, Blinded, Placebo- and Active-Controlled, Adaptive Phase 2 Clinical Trial to Evaluate the Immunogenicity and Safety of SYS6017 (a Herpes Zoster mRNA Vaccine) in Healthy Participants Aged 40 Years and Above".

02

Conditions studied

  • Herpes Zoster

Browse trials for

03

In context

Herpes Zoster

300 studies on the registry are indexed under Herpes Zoster; 56 are open to participants now.

This study's planned enrollment of 800 is above the median of 160 across 248 interventional studies indexed under Herpes Zoster.

Browse Herpes Zoster studies →

Lead sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd. is the lead sponsor of 42 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Individuals aged 40 years or older;
  • 2. Able to understand the study procedures, comply with the protocol requirements to attend all the scheduled visits, voluntarily consent to participate in the study, and sign the form;
  • 3. Is physically eligible at the discretion of investigators based on medical history inquiry and physical examination; For participants with chronic underlying diseases (e.g., diabetes mellitus, hypertension, hyperlipidemia and other chronic conditions), they may be enrolled if their conditions have been well controlled within 3 months prior to enrollment in this study (i.e., additional medical interventions or major adjustments to treatments are not required);
  • 4. For female participants of : No sexual activity or effective methods were used within one menstrual cycle before enrollment; No pregnancy plans and agree to adopt effective contraceptive methods within 8 months after enrollment.

Exclusion criteria

Exclusion Criteria:

  • 1. History of zoster;
  • 2. History of vaccination with varicella vaccine or zoster vaccine (including vaccine);
  • 3. Axillary temperature ≥ 37.1℃ on the day of enrollment or within 24 h before enrollment;
  • 4. History of allergy to any component of the investigational vaccine; or history of severe allergic reactions to vaccines or medications (including but not limited to anaphylaxis, allergic laryngeal edema, Henoch-Schönlein purpura, thrombocytopenic purpura, or Arthus reaction);
  • 5. History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or any condition that could increases the risk of myocarditis or pericarditis
  • 6. History of demyelinating diseases, including but not limited to Guillain-Barré syndrome, multiple sclerosis, ophthalmoneuromyelitis, acute disseminated encephalomyelitis, etc.;
  • 7. Current epilepsy or convulsion, severe neurological or psychiatric disorders;
  • 8. Have to intramuscular injection, e.g., diagnosed thrombocytopenia, any coagulation disorders, or ongoing treatment with anticoagulants, etc.;
  • 9. Active malignant tumor, malignant tumor without adequate treatment, malignant tumor with a potential risk of recurrence during the study;
  • 10. Active, unstable, severe or uncontrolled cardiovascular and cerebrovascular diseases, thrombotic diseases, blood and lymphatic system diseases, liver and kidney diseases, respiratory diseases, metabolic diseases, musculoskeletal diseases, diseases, etc;
  • 11. History of diagnosed immunocompromise or , congenital or functional asplenia, or splenectomy before enrollment;
  • 12. Long-term (defined as more than 14 consecutive days) systemic use of immunosuppressants, immunostimulants, or other immunomodulatory drugs (e.g., at a dose of ≥ 20 mg/day prednisone or equivalent) within 6 months prior to enrollment; however, inhaled and topical corticosteroids are permitted; or planned administration of the aforementioned agents during the study period;
  • 13. Administration of whole blood, plasma, serum, immunoglobulin, or monoclonal antibodies within 3 months prior to enrollment, or planned administration of the aforementioned products during the study period;
  • 14. Blood donation or blood loss ≥ 450 mL within one month before enrollment, or planning to donate blood during the study;
  • 15. Vaccination with any other vaccines within 30 days prior to enrollment, or planned vaccination with any other vaccines within 30 days after the last dose of the study vaccine;
  • 16. Current participation in or planned participation in other clinical trials during the study period;
  • 17. For female participants of : positive pregnancy test result prior to enrollment, current pregnancy or lactation, or planned pregnancy within 8 months after enrollment;
  • 18. Unable to comply with the study procedures and requirements, or presence of other conditions that make the participant inappropriate for this clinical trial, as judged by the investigators.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Dosage A of zoster mRNA vaccine SYS6017

    Biological: A zoster mRNA vaccine SYS6017

  • Experimental
    Dosage B of zoster mRNA vaccine SYS6017

    Biological: A zoster mRNA vaccine SYS6017

  • Experimental
    Dosage C of zoster mRNA vaccine SYS6017

    Biological: A zoster mRNA vaccine SYS6017

  • Experimental
    Dosage D of zoster mRNA vaccine SYS6017

    Biological: A zoster mRNA vaccine SYS6017

  • Experimental
    Dosage E of zoster mRNA vaccine SYS6017

    Biological: A zoster mRNA vaccine SYS6017

  • Placebo comparator
    Placebo

    Other: Placebo

  • Active comparator
    Active Comparator Vaccine

    Biological: Active Comparator Vaccine

Interventions

  • BiologicalA zoster mRNA vaccine SYS6017

    SYS6017,two-dose vaccination schedule (Month 0, 2)

  • OtherPlacebo

    0.9% saline,two-dose vaccination schedule (Month 0, 2)

  • BiologicalActive Comparator Vaccine

    Recombinant Zoster Vaccine (CHO cell),two-dose vaccination schedule (Month 0, 2)

06

What researchers measure

Primary outcomes

  1. solicited adverse events

    Time frame: within 14 days post each vaccination

  2. unsolicited adverse events

    Time frame: within 30 days post each vaccination

  3. Geometric Mean Concentration (GMC) of anti-gE antibody

    Time frame: On Day 14 and Day 30 after the completion of the full vaccination course

  4. Geometric Mean Fold Increase (GMFI) of anti-gE antibody

    Time frame: On Day 14 and Day 30 after the completion of the full vaccination course

  5. Seroconversion Rate (SCR) of anti-gE antibody

    Time frame: On Day 14 and Day 30 after the completion of the full vaccination course

Secondary outcomes

  1. serious adverse events

    Time frame: from the first vaccination through 12 months post the second vaccination

  2. adverse events of special interest

    Time frame: from the first vaccination through 12 months post the second vaccination

  3. pregnancy events reported by the participants

    Time frame: from the first vaccination through 12 months post the second vaccination

  4. Geometric Mean Titer (GMT) of anti-VZV antibody

    Time frame: On Day 14 after the completion of the full vaccination course

  5. Geometric Mean Fold Increase (GMFI) of anti-VZV antibody

    Time frame: On Day 14 after the completion of the full vaccination course

  6. Seroconversion Rate (SCR) of anti-VZV antibody

    Time frame: On Day 14 after the completion of the full vaccination course

  7. cellular immune response

    the frequency of peripheral blood mononuclear cell (PBMC) secreting gE-specific cytokines

    Time frame: On Day 14 and Day 30 after the completion of the full vaccination course

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Mar 2027, 14 months later.

Of 22 phase 2 interventional studies under Herpes Zoster, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 27. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 21, 2026
StartEst.
Jan 10, 2026
Primary completionEst.
Mar 10, 2027
CompletionEst.
May 31, 2027
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07354659
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Jan 10, 2026 (estimated)
Primary completion
Mar 10, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jan 21, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion